Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
,
Stéphanie Dufrechou
,
Julien Plenecassagnes
,
Isabelle Luquet
,
Odile Blanchet
(1)
,
Anne Banos
,
Marie Béné
,
Marc Bernard
,
Sarah Bertoli
,
Caroline Bonmati
,
Luc Matthieu Fornecker
,
Romain Guièze
,
Lamya Haddaoui
,
Mathilde Hunault
(1)
,
Jean Christophe Ianotto
,
Eric Jourdan
,
Mario Ojeda
,
Pierre Peterlin
,
Norbert Vey
(2)
,
Hacene Zerazhi
,
Hicheri Yosr
,
Ariane Mineur
,
Jean-Yves Cahn
,
Norbert Ifrah
(1)
,
Christian Récher
,
Arnaud Pigneux
,
Eric Delabesse
,
J.-P. Marolleau
,
A. Aleme
,
F. Orsini-Piocelle
,
N. Cadoux
,
C. Marie
,
A. Al jijakli
,
G. Lepeu
,
M. Beyrne
,
S. Labarrere
,
E. Deconinck
,
M. Peria
,
A. El Yamani
,
O. Kadiri
,
B. Choufi
,
M. Brument
,
T. Leguay
,
C. Berthou
,
G. Guillerm
,
G. Drugmanne
,
O. Tournilhac
(3)
,
G. Roy
,
B. Audhuy
,
S. Camara
,
D. Caillot
,
M. Grandjean
,
C.-E. Bulabois
,
B. Fief
,
C. Ladraa
,
V. Dorvaux
,
M. Hagopian
,
N. Fegueux
,
C. Fenoll
,
V. Sabadash
,
C. Haby
,
F. Witz
,
M. Lhuire
,
J. Delaunay
,
L. Airiau
,
L. Mannone
,
I. Touitou
,
D. Umuhire
,
M. Alexis
,
O. Michel
,
F. Dreyfus
,
D. Bouscary
,
A. Cheung
,
L. Sanhes
,
F. Touhami
,
E. Ribas
,
M. Puyade
,
M.-P. Gallego-Hernanz
,
N. Hugon
,
C. Himberlin
,
L. Maggi
,
T. Lamy
,
A. Testu
,
E. Tavernier
,
S. Marchand
,
B. Lioure
,
C. Kravanja
,
L. Benboubker
,
D. Nollet
,
M. Attal
,
A. Sarry
,
A. Lhermitte
,
G. Yrica
,
D. Schwartz
,
N. Le Montagner
,
L. Auvray
,
R. Delepine
,
A. Fayault
Laetitia Largeaud
- Function : Author
- PersonId : 803089
- ORCID : 0000-0001-5341-5427
Pascale Cornillet-Lefebvre
- Function : Author
Jean-François Hamel
- Function : Author
Pierre-Yves Dumas
- Function : Author
- PersonId : 783354
- ORCID : 0000-0003-0119-3548
Naïs Prade
- Function : Author
- PersonId : 814303
- ORCID : 0000-0003-4718-7848
Stéphanie Dufrechou
- Function : Author
Julien Plenecassagnes
- Function : Author
Isabelle Luquet
- Function : Author
Anne Banos
- Function : Author
Marie Béné
- Function : Author
- PersonId : 767851
- ORCID : 0000-0002-6569-7414
Marc Bernard
- Function : Author
Sarah Bertoli
- Function : Author
- PersonId : 1065139
- ORCID : 0000-0003-1084-2781
Caroline Bonmati
- Function : Author
Luc Matthieu Fornecker
- Function : Author
Romain Guièze
- Function : Author
Lamya Haddaoui
- Function : Author
Mathilde Hunault
- Function : Author
- PersonId : 752203
- IdHAL : mathilde-hunault-berger
- ORCID : 0000-0001-7777-5216
Jean Christophe Ianotto
- Function : Author
Eric Jourdan
- Function : Author
Mario Ojeda
- Function : Author
Pierre Peterlin
- Function : Author
- PersonId : 776625
- ORCID : 0000-0001-5463-6686
Norbert Vey
- Function : Author
- PersonId : 762211
- ORCID : 0000-0001-7027-040X
Hacene Zerazhi
- Function : Author
Hicheri Yosr
- Function : Author
Ariane Mineur
- Function : Author
Jean-Yves Cahn
- Function : Author
Christian Récher
- Function : Author
- PersonId : 975639
- ORCID : 0000-0002-3332-4525
- IdRef : 134542487
Arnaud Pigneux
- Function : Author
Eric Delabesse
- Function : Author
- PersonId : 769021
- ORCID : 0000-0002-0928-0753
J.-P. Marolleau
- Function : Author
- PersonId : 887235
- IdRef : 06981676X
A. Aleme
- Function : Author
F. Orsini-Piocelle
- Function : Author
N. Cadoux
- Function : Author
C. Marie
- Function : Author
A. Al jijakli
- Function : Author
G. Lepeu
- Function : Author
M. Beyrne
- Function : Author
S. Labarrere
- Function : Author
E. Deconinck
- Function : Author
M. Peria
- Function : Author
A. El Yamani
- Function : Author
O. Kadiri
- Function : Author
B. Choufi
- Function : Author
M. Brument
- Function : Author
T. Leguay
- Function : Author
C. Berthou
- Function : Author
G. Guillerm
- Function : Author
G. Drugmanne
- Function : Author
G. Roy
- Function : Author
B. Audhuy
- Function : Author
S. Camara
- Function : Author
D. Caillot
- Function : Author
M. Grandjean
- Function : Author
C.-E. Bulabois
- Function : Author
B. Fief
- Function : Author
C. Ladraa
- Function : Author
V. Dorvaux
- Function : Author
M. Hagopian
- Function : Author
N. Fegueux
- Function : Author
C. Fenoll
- Function : Author
V. Sabadash
- Function : Author
C. Haby
- Function : Author
F. Witz
- Function : Author
M. Lhuire
- Function : Author
J. Delaunay
- Function : Author
L. Airiau
- Function : Author
L. Mannone
- Function : Author
I. Touitou
- Function : Author
D. Umuhire
- Function : Author
M. Alexis
- Function : Author
O. Michel
- Function : Author
F. Dreyfus
- Function : Author
D. Bouscary
- Function : Author
A. Cheung
- Function : Author
L. Sanhes
- Function : Author
F. Touhami
- Function : Author
E. Ribas
- Function : Author
M. Puyade
- Function : Author
M.-P. Gallego-Hernanz
- Function : Author
N. Hugon
- Function : Author
C. Himberlin
- Function : Author
L. Maggi
- Function : Author
T. Lamy
- Function : Author
A. Testu
- Function : Author
E. Tavernier
- Function : Author
S. Marchand
- Function : Author
- PersonId : 760284
- ORCID : 0000-0001-5279-6678
- IdRef : 059397454
B. Lioure
- Function : Author
C. Kravanja
- Function : Author
L. Benboubker
- Function : Author
D. Nollet
- Function : Author
M. Attal
- Function : Author
- PersonId : 944589
A. Sarry
- Function : Author
A. Lhermitte
- Function : Author
G. Yrica
- Function : Author
D. Schwartz
- Function : Author
N. Le Montagner
- Function : Author
L. Auvray
- Function : Author
R. Delepine
- Function : Author
A. Fayault
- Function : Author
Abstract
We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3A were the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.
Domains
Cancer
Origin : Files produced by the author(s)